PARP-1及其抑制剂与肿瘤发生、发展及放射敏感性关系研究进展

doi:10.3760/cma.j.issn.1004-4221.2017.11.024

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (819 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

Poly (ADP-ribose) polymerase-1(PARP-1), a ubiquitous and abundant nuclear protein composed of amino-acid residues, plays an important role in the process of DNA damage repair. In recent years, some studies have confirmed that PARP-1 is closely related to the development and progression of tumors, and may influence the tumor radiosensitivity. This article summarizes the relationship of PARP-1 and its inhibitors and the development, progression, and radiosensitivity of tumors.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Li Lingling
	Zhao Yuxia

Key words： Poly ADP-ribose polymerase-1 Inhibitor Tumor Radiosensitivity

Received: 08 October 2016

Cite this article:

Li Lingling,Zhao Yuxia. Research advances in the relationship between PARP-1 and its inhibitors and the development, progression, and radiosensitivity of tumors[J]. Chinese Journal of Radiation Oncology, 2017, 26(11): 1350-1353.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.11.024 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I11/1350

[1] K tter A,Cornils K,Borgmann K,et al. Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells[J].Mol Oncol,2014,8(8):1616-1625.DOI:10.1016/j.molonc.2014.06.008.
[2] Prasad NR,Muthusamy G,Shanmugam M,et al. South Asian medicinal compounds as modulators of resistance to chemotherapy and radiotherapy[J].Cancers,2016,8(3):32.DOI:10.3390/cancers8030032.
[3] Salehifar E,Hosseinimehr SJ.The use of cyclooxygenase-2 inhibitors for improvement of efficacy of radiotherapy in cancers[J].Drug Discov Today,2016,21(4):654-662.DOI:10.1016/j.drudis.2016.02.019.
[4] Malyuchenko NV,Kotova EY,Kulaeva OI,et al. PARP1 inhibitors:antitumor drug design[J].Acta Naturae,2015,7(3):27-37.
[5] Daugherty MD,Young JM,Kerns JA,et al. Rapid evolution of PARP genes suggests a broad role for ADP-ribosylation in host-virus conflicts[J].PLoS Genet,2014,10(5):e1004403.DOI:10.1371/journal.pgen.1004403.
[6] Nalabothula N,Al-Jumaily T,Eteleeb AM,et al. Genome-wide profiling of PARP1 reveals an interplay with gene regulatory regions and DNA methylation[J].PLoS One,2015,10(8):e0135410.DOI:10.1371/journal.pone.0135410.
[7] Salvati E,Scarsella M,Porru M,et al. PARP1 is activated at telomeres upon G4 stabilization:possible target for telomere-based therapy[J].Oncogene,2010,29(47):6280-6293.DOI:10.1038/onc.2010.344.
[8] Deshmukh D,Qiu Y.Role of PARP-1 in prostate cancer[J].Am J Clin Exp Urol,2015,3(1):1-12.
[9] Ali AAE,Timinszky G,Arribas-Bosacoma R,et al. The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks[J].Nat Struct Mol Biol,2012,19(7):685-692.DOI:10.1038/nsmb.2335.
[10] Huambachano O,Herrera F,Rancourt A,et al. Double-stranded DNA binding domain of poly (ADP-ribose) polymerase-1 and molecular insight into the regulation of its activity[J].J Biol Chem,2011,286(9):7149-7160.DOI:10.1074/jbc. M110.175190.
[11] Gonalves A,Finetti P,Sabatier R,et al. Poly (ADP-ribose) polymerase-1 mRNA expression in human breast cancer:a meta-analysis[J].Breast Cancer Res Treat,2011,127(1):273-281.DOI:10.1007/s10549-010-1199-y.
[12] Galia A,Calogero AE,Condorelli RA,et al. PARP-1 protein expression in glioblastoma multiforme[J].Eur J Histochem,2012,56(1):e9.DOI:10.4081/ejh.2012.e9.
[13] Gagné JP,Ethier C,Defoy D,et al. Quantitative site-specific ADP-ribosylation profiling of DNA-dependent PARPs[J].DNA Repair,2015,30:68-79.DOI:10.1016/j.dnarep.2015.02.004.
[14] Winiknik E,Ryksa M,Koter-Michalak M.PARP1 inhibitors:contemporary attempts at their use in anticancer therapy and future perspective[J].Postepy Hig Med Dosw,2016,70:280-294.
[15] Vyas S,Chang P.New PARP targets for cancer therapy[J].Nat Rev Cancer,2014,14(7):502-509.DOI:10.1038/nrc3748.
[16] Krishnakumar R,Kraus WL.The PARP side of the nucleus:molecular actions,physiological outcomes,and clinical targets[J].Mol Cell,2010,39(1):8-24.DOI:10.1016/j.molcel.2010.06.017.
[17] García S,Conde C.The role of poly (ADP-ribose) polymerase-1 in rheumatoid arthritis[J].Mediators Inflamm,2015,2015:837250.DOI:10.1155/2015/837250.
[18] O′Neil NJ,van Pel DM,Hieter P.Synthetic lethality and cancer:cohesin and PARP at the replication fork[J].Trends Genet,2013,29(5):290-297.DOI:10.1016/j.tig.2012.12.004.
[19] Sousa FG,Matuo R,Soares DG,et al. PARPs and the DNA damage response[J].Carcinogenesis,2012,33(8):1433-1440.DOI:10.1093/carcin/bgs132.
[20] Dianov GL,Hübscher U.Mammalian base excision repair:the forgotten archangel[J].Nucleic Acids Res,2013,41(6):3483-3490.DOI:10.1093/nar/gkt076.
[21] Bryant HE,Petermann E,Schultz N,et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination[J].EMBO J,2009,28(17):2601-2615.DOI:10.1038/emboj.2009.206.
[22] Yang YG,Cortes U,Patnaik S,et al. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks,but compromises the reactivation of stalled replication forks[J].Oncogene,2004,23(21):3872-3882.DOI:10.1038/sj.onc.1207491.
[23] Hunter JE,Willmore E,Irving JA,et al. NF-κB mediates radio-sensitization by the PARP-1 inhibitor,AG-014699[J].Oncogene,2012,31(2):251-264.DOI:10.1038/onc.2011.229.
[24] Mladenov E,Iliakis G.Induction and repair of DNA double strand breaks:the increasing spectrum of non-homologous end joining pathways[J].Mutat Res,2011,711(1-2):61-72.DOI:10.1016/j.mrfmmm.2011.02.005.
[25] Hall EJ.Radiobiology for the radiologist[M].5th Ed. New York:Lippincott Williams& Wilkins 2000.
[26] Lucchesi JC.Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster[J].Genetics,1968,59(1):37-44.
[27] Dobzhansky T.Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila pseudoobscura[J].Genetics,1946,31(3):269-290.
[28] Thompson JM,Nguyen QH,Singh M,et al. Approaches to identifying synthetic lethal interactions in cancer[J].Yale J Biol Med,2015,88(2):145-155.
[29] Farmer H,McCabe N,Lord CJ,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy[J].Nature,2005,434(7035):917-921.DOI:10.1038/nature03445.
[30] Bryant HE,Schultz N,Thomas HD,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase[J].Nature,2005,434(7035):913-917.DOI:10.1038/nature03443.
[31] Wurster S,Hennes F,Parplys AC,et al. PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response[J].Oncotarget,2016,7(9):9732-9741.DOI:10.18632/oncotarget.6947.
[32] Knittel G,Liedgens P,Reinhardt HC.Targeting ATM-deficient CLL through interference with DNA repair pathways[J].Front Genet,2015,6:207.DOI:10.3389/fgene.2015.00207.
[33] Wen Q,Scorah J,Phear G,et al. A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner[J].Mol Biol Cell,2008,19(4):1693-1705.DOI:10.1091/mbc. E07-09-0975.
[34] Vilar E,Bartnik CM,Stenzel SL,et al. MRE11 deficiency increases sensitivity to poly (ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers[J].Cancer Res,2011,71(7):2632-2642.DOI:10.1158/0008-5472.CAN-10-1120.
[35] Williamson CT,Muzik H,Turhan AG,et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly (ADP-ribose) polymerase-1 inhibitors[J].Mol Cancer Ther,2010,9(2):347-357.DOI:10.1158/1535-7163.MCT-09-0872.
[36] Majuelos-Melguizo J,Rodríguez MI,López-Jiménez L,et al. PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma[J].Oncotarget,2015,6(7):4790-4803.DOI:10.18632/oncotarget.2993.
[37] Wang YM,Huang JW,Calses P,et al. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition[J].Cancer Res,2012,72(16):4037-4046.DOI:10.1158/0008-5472.CAN-12-0103.
[38] Chow JPH,Man WY,Mao M,et al. PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy[J].Mol Cancer Ther,2013,12(11):2517-2528.DOI:10.1158/1535-7163.MCT-13-0010.
[39] Ossovskaya V,Koo IC,Kaldjian EP,et al. Upregulation of poly (ADP-ribose) polymerase-1(PARP1) in triple-negative breast cancer and other primary human tumor types[J].Genes Cancer,2010,1(8):812-821.DOI:10.1177/1947601910383418.
[40] Kossatz S,Weber WA,Reiner T.Optical imaging of PARP1 in response to radiation in oral squamous cell carcinoma[J].PLoS One,2016,11(1):e0147752.DOI:10.1371/journal.pone.0147752.
[41] Quiles-Perez R,Muoz-Gámez JA,Ruiz-Extremera,et al. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression[J].Hepatology,2010,51(1):255-266.DOI:10.1002/hep.23249.
[42] 刘彭坤,郝吉庆.PARP-1、P-gp和 LRP在肺腺癌中的表达和相关性研究[J].安徽医药,2014,18(5):851-854.DOI:10.3969/j.issn.1009-6469.2014.05.017.
Liu PK,Hao JQ.The expression of PARP-1,P-gp,LRP and their correlation in lung adenocarcinoma[J].Anhui Med Pharm J,2014,18(5):851-854.DOI:10.3969/j.issn.1009-6469.2014.05.017.
[43] Salemi M,Galia A,Fraggetta F,et al. Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue[J].Eur J Histochem,2013,57(2):e13.DOI:10.4081/ejh.2013.e13.
[44] Li ZH,Lv T,Liu YY,et al. PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma[J].Cancer Biomark,2016,16(4):633-639.DOI:10.3233/CBM-160605.
[45] Veuger SJ,Hunter JE,Durkacz BW.Ionizing radiation-induced NF-κB activation requires PARP-1 function to confer radioresistance[J].Oncogene,2009,28(6):832-842.DOI:10.1038/onc.2008.439.
[46] Hsu HW,Gridley DS,Kim PD,et al. Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells[J].Oral Oncol,2013,49(6):591-597.DOI:10.1016/j.oraloncology.2013.02.009.
[47] Ahmed SU,Carruthers R,Gilmour L,et al. Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells[J].Cancer Res,2015,75(20):4416-4428.DOI:10.1158/0008-5472.CAN-14-3790.
[48] Han SM,Brenner JC,Sabolch A,et al. Targeted radiosensitization of ETS fusion–positive prostate cancer through PARP1 inhibition[J].Neoplasia,2013,15(10):1207-1217.DOI:10.1593/neo.131604.
[49] Vance S,Liu EQ,Zhao LL,et al. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1[J].Cell Cycle,2011,10(24):4321-4329.DOI:10.4161/cc.10.24.18661.
[50] Tuli R,Surmak AJ,Reyes J,et al. Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888[J].Transl Oncol,2014,7(3):439-445.DOI:10.1016/j.tranon.2014.04.003.
[51] Karnak D,Engelke CG,Parsels LA,et al. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer[J].Clin Cancer Res,2014,20(19):5085-5096.DOI:10.1016/j.tranon.2014.04.003.
[52] Zhou ZR,Zhu XD,Zhao W,et al. Poly (ADP-ribose) polymerase-1 regulates the mechanism of irradiation-induced CNE-2 human nasopharyngeal carcinoma cell autophagy and inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells[J].Oncol Rep,2013,29(6):2498-2506.DOI:10.3892/or.2013.2382.
[53] Chen ZT,Zhao W,Qu S,et al. PARP-1 promotes autophagy via the AMPK/mTOR pathway in CNE-2 human nasopharyngeal carcinoma cells following ionizing radiation,while inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells[J].Mol Med Rep,2015,12(2):1868-1876.DOI:10.3892/mmr.2015.3604.
[54] Domínguez-Gómez G,Díaz-Chávez J,Chávez-Blanco A,et al. Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin[J].Oncol Rep,2015,33(2):721-728.DOI:10.3892/or.2014.3661.
[55] Feng FY,Speers C,Liu ML,et al. Targeted radiosensitization with PARP1 inhibition:optimization of therapy and identification of biomarkers of response in breast cancer[J].Breast Cancer Res Treat,2014,147(1):81-94.DOI:10.1007/s10549-014-3085-5.
[56] Calabrese CR,Almassy R,Barton S,et al. Anticancer Chemosensitization and Radiosensitization by the Novel Poly (ADP-ribose) Polymerase-1 Inhibitor AG14361[J].J Natl Cancer Inst,2004,96(1):56-67.DOI:10.1093/jnci/djh005.
[57] 王维,段碧霞,曾丽.PARP抑制剂对Lewis肺癌细胞及移植瘤放疗增敏作用及其机制[J].中国肺癌杂志,2016,19(1):16-23.DOI:10.3779/j.issn.1009-3419.2016.01.02
Wang W,Duan BX,Zeng L.Effect and mechanism of radiosensitization of poly (ADP-Ribose) polymerase inhibitor on lewis cells and xenografts[J].Chin J Lung Cancer,2016,19(1):16-23.DOI:10.3779/j.issn.1009-3419.2016.01.02
[58] Azad A,Bukczynska P,Jackson S,et al. Co-targeting deoxyribonucleic acid-dependent protein kinase and poly (adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells[J].Int J Radiat Oncol Biol Phys,2014,88(2):385-394.DOI:10.1016/j.ijrobp.2013.10.043.
[59] Godon C,Cordelières FP,Biard D,et al. PARP inhibition versus PARP-1 silencing:different outcomes in terms of single-strand break repair and radiation susceptibility[J].Nucleic Acids Res,2008,36(13):4454-4464.DOI:10.1093/nar/gkn403.